Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work
Biogen scales back Apellis programs, trims research roles after $5.6 ...
Biogen ends Apellis research programs, cuts roles after buyout
Apellis Surges 135% in One Day While Gene Therapy Stocks Crash — 8 ...
Biogen to Acquire Apellis Pharmaceuticals for $41.00 Per Share
FinancialContent - Biogen Acquires Apellis Pharmaceuticals in $5.6 ...
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After ...
Biogen to acquire Apellis for $5.6 billion
Apellis Pharmaceuticals CFO sells shares worth $93,953
Apellis Pharmaceuticals' Q1 2025: Unraveling Contradictions in Co-Pay ...
Apellis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Apellis to Receive up to $300 Million from Royalty Purchase Agreement ...
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan ...
Insider Selling and Market Implications for Apellis Pharmaceuticals (APLS)
Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M
Apellis Stock Crashes 23% in a Week: Here's What | SwingTradeBot.com
Biogen axes 'small number' of Apellis roles after $5.6B buy - BioSpace
Biogen Completes $5.3 Billion Acquisition of Apellis Pharmaceuticals
FinancialContent - Apellis Pharmaceuticals Reports Fourth Quarter and ...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 ...
Apellis
Biogen Completes acquisition of Apellis Pharmaceuticals
StockWatch: Apellis Wows Analysts with First FDA Approval for GA Therapy
Apellis Pharmaceuticals raises $350 million in public offering ...
Apellis Pharmaceuticals Showcases Promising Research at ASRS 2025 ...
AAO 2023: Apellis Pharmaceuticals reveals GALE extension study results ...
Apellis Announces US FDA Approval of the EMPAVELI Injector, a Device to ...
Apellis Pharmaceuticals’ Phase 3 Study on Pegcetacoplan: A Potential ...
Apellis Receives FDA Approval for SYFOVRE™ (pegcetacoplan injection) as ...
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli’s New ...
Mizuho Raises Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $41 ...
How Does Apellis Pharmaceuticals Company Work? – Pestel-analysis.com
Biogen buys Apellis for $5.6B to bolster immunology and kidney disease ...
Apellis will appeal CHMP’s rejection of pegcetacoplan | pharmaphorum
Biogen to Acquire Apellis Pharmaceuticals in $5.6 Billion Deal: A High ...
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Presents a Compelling Growth ...
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Fits the 'Growth at a ...
Apellis (APLS) Stock Up 50% in Three Months: Here's Why?
Investing in Apellis Pharmaceuticals (APLS): Navigating the Thin Line ...
Apellis raises uncommon eye disease profile with ‘The Fonz’ actor Henry ...
Apellis Pharmaceuticals Inc's Chief Development Officer Sells Company ...
Sobi and Apellis report new results from VALIANT trial | Clinical ...
Apellis Pharmaceuticals (APLS) Stock Rockets 136% on $5.6B Biogen ...
Apellis Pharma down 37% - $4 billion in value wiped out in one day
Apellis logo hi-res stock photography and images - Alamy
Apellis releases 24-month results of phase 3 studies for GA treatment
Apellis Pharmaceuticals on LinkedIn: Today, we are proud to announce a ...
Earnings To Watch: Apellis Pharmaceuticals Inc (APLS) Reports Q3 2025 ...
Apellis Pharma Price Prediction: Will APLS Stock, Take Support? - The ...
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion, Expanding ...
Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS ...
Apellis Pharmaceuticals Reports Promising Phase 3 VALIANT Study Results ...
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion
Apellis Pharmaceuticals on LinkedIn: Apellis Announces Preliminary U.S ...
Is Apellis Set for a Rebound?
Apellis and Iveric bio Announce Updates to their FDA Submissions for ...
Apellis appoints Caroline Baumal, MD, as chief medical officer
Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P ...
CHMP turns down Neuraxpharm, Apellis drugs | pharmaphorum
#era2024 | Apellis Pharmaceuticals
Apellis Pharmaceuticals on LinkedIn: #teamapellis #weareapellis
Apellis Pharmaceuticals on LinkedIn: Our Science
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in ...
Apellis Pharmaceutical's 10,000 Square Foot Conversion - PIDC Construction
Apellis provides update on cases of retinal vasculitis among patients ...
Apellis Pharmaceuticals on LinkedIn: #jpm24
Apellis snatches broad kidney disease expansion for Empaveli
Apellis Pharmaceuticals on LinkedIn: #weareapellis
Apellis Pharmaceuticals on LinkedIn: The Conference Exchange (TM ...
Apellis Pharmaceuticals on LinkedIn: #asrs2024 #geographicatrophy # ...
Apellis Pharma skyrockets on Biogen deal. Is it too late to chase APLS ...
Stocks to Watch Tuesday: McCormick, Unilever, Marvell, Centessa, Apellis
Apellis Pharma attracts takeover interest from larger drug makers ...
Apellis surges on $5.6B buyout deal with Biogen
Apellis Pharmaceuticals on LinkedIn: #teamapellis #arvo2024 # ...
Apellis Pharmaceuticals Inc: Apellis Pharma's eye-disorder drug gets ...
Bonos Apellis Pharmaceuticals, Inc.: tipos bonos corp. — TradingView
Apellis Pharmaceuticals, Inc. Trademarks & Logos
Apellis Pharmaceuticals Inc. offers additional common stock and sets ...
Official Home Page of the Apellis Pharmaceuticals Corporate Site ...
Apellis Pharmaceuticals logo in transparent PNG and vectorized SVG formats
Career Opportunities and Benefit Programs | Apellis Pharmaceuticals
Apellis Pharmaceuticals - PIDC Construction
Apellis Pharmaceuticals Event Case Study | Global Event Delivery
Working at Apellis Pharmaceuticals | Top Workplaces
Apellis Pharmaceuticals, Inc. Announces Major Business Developments ...
Home - Apellis Medical Hub
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device ...
Apellis Pharmaceuticals Jobs and Company Culture | Powderkeg
Apellis, AstraZeneca break down their #FierceMadness success
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in ...
Biogen Q1 Revenue Rises 2% to $2.5 Billion
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and ...
Biogen’s $5.6B All-In on Apellis: Binary 2027 Earnings Make or Break ...
Global Health Updates: Ebola Efforts and Pharmaceutical Developments ...
APLS Q3 2025 Earnings Report on 10/30/2025
US Stock Market Today | Dow Jones | Nasdaq Highlights: Dow soars 1,125 ...
APLS Q1 2026 Earnings Report on 5/7/2026
Apellis’ Empaveli Expansion Underway In Rare Kidney Disease
Apellis’ Geographic Atrophy Treatment Rejected Again by EMA - Media MICE
Appellis Pharmaceuticals in Waltham laying off 175 employees – NBC Boston
First-to-Market Edge for Apellis’s Syfovre in Geographic
.jpg?VersionId=pf5l0gVUHV36aNKY3vN8EUzYL8ntWwBo)
